Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Should You Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $18.84, but opened at $18.07. Daiichi Sankyo shares last traded at $18.20, with a volume of 1,913 shares traded.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DSNKY. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The firm has a market capitalization of $34.99 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 2.59 and a beta of -0.11. The firm’s 50 day moving average price is $17.58 and its 200-day moving average price is $17.25.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.